Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
The art of drug synthesis / / edited by Douglas S. Johnson, Jie Jack Li
| The art of drug synthesis / / edited by Douglas S. Johnson, Jie Jack Li |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J. : , : Wiley-Interscience, , 2007 |
| Descrizione fisica | 1 online resource (xv, 276 pages) : illustrations |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
JohnsonDouglas S <1968-> (Douglas Scott)
LiJie Jack |
| Collana | Wiley Series on Drug Synthesis |
| Soggetto topico |
Drugs - Design
Pharmaceutical chemistry |
| ISBN |
1-118-67846-X
1-280-91677-X 9786610916771 0-470-13497-6 0-470-13496-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
THE ART OF DRUG SYNTHESIS; CONTENTS; Foreword; Preface; Contributors; 1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY; 1.1 Introduction; 1.2 Hurdles in the Drug Discovery Process; 1.3 The Tools of Medicinal Chemistry; 1.3.1 In Silico Modeling; 1.3.2 Structure-Based Drug Design (SBDD); 1.4 The Role of Synthetic Chemistry in Drug Discovery; References; 2 PROCESS RESEARCH: HOW MUCH? HOW SOON?; 2.1 Introduction; 2.2 Considerations for Successful Scale-up to Tox Batches and Phase I Material; 2.3 Considerations for Phase 2 Material and Beyond; 2.3.1 Reagent Selection; 2.3.2 Solvent Selection
2.3.3 Unit Operations; 2.3.4 Developing Simple, Effective, Efficient Work-ups and Isolations; 2.3.5 The Importance of Physical States; 2.3.6 Route Design and Process Optimization to Minimize COG; 2.4 Summary; References; I CANCER AND INFECTIOUS DISEASES; 3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN®), ANASTROZOLE (ARIMIDEX®), AND LETROZOLE (FEMARA®); 3.1 Introduction; 3.2 Synthesis of Exemestane; 3.3 Synthesis of Anastrozole; 3.4 Synthesis of Letrozole; References 4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN®), MOXIFLOXACIN (AVELOX®), GEMIFLOXACIN (FACTIVE®), AND GARENOXACIN (T-3811)4.1 Introduction; 4.1.1 Mechanism of Action; 4.1.2 Modes of Resistance; 4.1.3 Structure-Activity Relationship (SAR) and Structure-Toxicity Relationship (STR); 4.1.4 Pharmacokinetics; 4.1.5 Synthetic Approaches; 4.2 Levofloxacin; 4.3 Moxifloxacin; 4.4 Gemifloxacin; 4.5 Garenoxacin (T-3811): A Promising Clinical Candidate; References; 5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX®), FLUCONAZOLE (DIFLUCAN®), VORICONAZOLE (VFEND®), AND FOSFLUCONAZOLE (PRODIF®) 5.1 Introduction; 5.2 Synthesis of Itraconazole; 5.3 Synthesis of Fluconazole; 5.4 Synthesis of Voriconazole; 5.5 Synthesis of Fosfluconazole; References; 6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS; 6.1 Introduction; 6.2 Synthesis of Nevirapine; 6.3 Synthesis of Efavirenz; 6.4 Synthesis of Delavirdine Mesylate; References; 7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU®) AND ZANAMIVIR (RELENZA®); 7.1 Introduction; 7.1.1 Relenza; 7.1.2 Tamiflu; 7.2 Synthesis of Oseltamivir Phosphate (Tamiflu®); 7.3 Synthesis of Zanamivir (Relenza®); References II CARDIOVASCULAR AND METABOLIC DISEASES; 8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES; 8.1 Introduction; 8.1.1 Insulin; 8.1.2 Sulfonylurea Drugs; 8.1.3 Meglitinides; 8.1.4 Biguanides; 8.1.5 Alpha-Glucosidase Inhibitors; 8.1.6 Thiazolidinediones; 8.2 Synthesis of Rosiglitazone; 8.3 Synthesis of Pioglitazone; 8.4 Synthesis of Muraglitazar; References; 9 ANGIOTENSIN AT(1) ANTAGONISTS FOR HYPERTENSION; 9.1 Introduction; 9.2 Losartan Potassium; 9.2.1 Introduction to Losartan Potassium; 9.2.2 Synthesis of Losartan Potassium; 9.3 Valsartan; 9.3.1 Introduction to Valsartan |
| Record Nr. | UNINA-9910143402603321 |
| Hoboken, N.J. : , : Wiley-Interscience, , 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
C-H bond activation in organic synthesis / / edited by Jie Jack Li, University of San Francisco, California, USA
| C-H bond activation in organic synthesis / / edited by Jie Jack Li, University of San Francisco, California, USA |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , [2015] |
| Descrizione fisica | 1 online resource (320 p.) |
| Disciplina |
547.27
547/.27 |
| Soggetto topico |
Organic compounds - Synthesis
Activation (Chemistry) Analytical chemistry Carbon Hydrogen |
| ISBN | 0-429-06948-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | chapter 1. Introduction / Marion H. Emmert -- chapter 2. Radical-mediated C-H bond activation / Adam M. Azman -- chapter 3. Pd-catalyzed C-H functionalization / Jesse D. Carrick -- chapter 4. Rhodium-catalyzed C-H activation / Micheal Fultz -- chapter 5. Nickel-catalyzed C-H activation / Andrew C. Williams -- chapter 6. Iron-catalyzed C-H activation / Narendra B. Ambhaikar -- chapter 7. Copper-mediated C-H activation / Nadia M. Ahmad -- chapter 8. Cobalt-catalyzed C-H activation / Nicole L. Snyder and Eric J. Medici -- chapter 9. Fluorination and trifluoromethylation of arenes and heteroarenes via C-H activation / Ji Zhang and Timothy T. Curran -- chapter 10. C-H activation of heteroaromatics / Donna A.A. Wilton. |
| Altri titoli varianti | Carbon-hydrogen bond activation in organic synthesis |
| Record Nr. | UNINA-9910788021903321 |
| Boca Raton : , : CRC Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
C-H bond activation in organic synthesis / / edited by Jie Jack Li, University of San Francisco, California, USA
| C-H bond activation in organic synthesis / / edited by Jie Jack Li, University of San Francisco, California, USA |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , [2015] |
| Descrizione fisica | 1 online resource (320 p.) |
| Disciplina |
547.27
547/.27 |
| Soggetto topico |
Organic compounds - Synthesis
Activation (Chemistry) Analytical chemistry Carbon Hydrogen |
| ISBN | 0-429-06948-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | chapter 1. Introduction / Marion H. Emmert -- chapter 2. Radical-mediated C-H bond activation / Adam M. Azman -- chapter 3. Pd-catalyzed C-H functionalization / Jesse D. Carrick -- chapter 4. Rhodium-catalyzed C-H activation / Micheal Fultz -- chapter 5. Nickel-catalyzed C-H activation / Andrew C. Williams -- chapter 6. Iron-catalyzed C-H activation / Narendra B. Ambhaikar -- chapter 7. Copper-mediated C-H activation / Nadia M. Ahmad -- chapter 8. Cobalt-catalyzed C-H activation / Nicole L. Snyder and Eric J. Medici -- chapter 9. Fluorination and trifluoromethylation of arenes and heteroarenes via C-H activation / Ji Zhang and Timothy T. Curran -- chapter 10. C-H activation of heteroaromatics / Donna A.A. Wilton. |
| Altri titoli varianti | Carbon-hydrogen bond activation in organic synthesis |
| Record Nr. | UNINA-9910812358903321 |
| Boca Raton : , : CRC Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Contemporary drug synthesis / / Jie Jack Li [et al.]
| Contemporary drug synthesis / / Jie Jack Li [et al.] |
| Pubbl/distr/stampa | Hoboken, N.J. : , : Wiley-Interscience, , 2004 |
| Descrizione fisica | 1 online resource (xv, 221 pages) : illustrations |
| Disciplina | 615/.31 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Design |
| ISBN |
1-280-27291-0
9786610272914 0-470-23708-2 0-471-68673-5 0-471-68674-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction
3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References |
| Record Nr. | UNINA-9910146084303321 |
| Hoboken, N.J. : , : Wiley-Interscience, , 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Contemporary drug synthesis / / Jie Jack Li [et al.]
| Contemporary drug synthesis / / Jie Jack Li [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J. : , : Wiley-Interscience, , 2004 |
| Descrizione fisica | 1 online resource (xv, 221 pages) : illustrations |
| Disciplina | 615/.31 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Design |
| ISBN |
1-280-27291-0
9786610272914 0-470-23708-2 0-471-68673-5 0-471-68674-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction
3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References |
| Record Nr. | UNINA-9910818441403321 |
| Hoboken, N.J. : , : Wiley-Interscience, , 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Contemporary drug synthesis / / Jie Jack Li [et al.]
| Contemporary drug synthesis / / Jie Jack Li [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J. : , : Wiley-Interscience, , 2004 |
| Descrizione fisica | 1 online resource (xv, 221 pages) : illustrations |
| Disciplina | 615/.31 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Design |
| ISBN |
1-280-27291-0
9786610272914 0-470-23708-2 0-471-68673-5 0-471-68674-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction
3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References |
| Record Nr. | UNISA-996211665003316 |
| Hoboken, N.J. : , : Wiley-Interscience, , 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Drug discovery [[electronic resource] ] : practices, processes, and perspectives / / edited by Jie Jack Li, E.J. Corey
| Drug discovery [[electronic resource] ] : practices, processes, and perspectives / / edited by Jie Jack Li, E.J. Corey |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2013 |
| Descrizione fisica | 1 online resource (572 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
LiJie Jack
CoreyE. J |
| Soggetto topico |
Drug development
Pharmaceutical chemistry |
| ISBN |
1-118-35447-8
1-118-35448-6 1-299-46484-X 1-118-35446-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | History of drug discovery -- Target identification and validation -- In vitro and in vivo assays -- Drug metabolism and pharmacokinetics in drug discovery -- Cardiovascular drugs -- Diabetes drugs -- CNS drugs -- Cancer drugs -- Antiinflammatory and immunomodulatory drugs -- Anti-bacterial drugs -- Antiviral drug discovery. |
| Record Nr. | UNINA-9910139018803321 |
| Hoboken, N.J., : John Wiley & Sons, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug discovery [[electronic resource] ] : practices, processes, and perspectives / / edited by Jie Jack Li, E.J. Corey
| Drug discovery [[electronic resource] ] : practices, processes, and perspectives / / edited by Jie Jack Li, E.J. Corey |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2013 |
| Descrizione fisica | 1 online resource (572 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
LiJie Jack
CoreyE. J |
| Soggetto topico |
Drug development
Pharmaceutical chemistry |
| ISBN |
1-118-35447-8
1-118-35448-6 1-299-46484-X 1-118-35446-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | History of drug discovery -- Target identification and validation -- In vitro and in vivo assays -- Drug metabolism and pharmacokinetics in drug discovery -- Cardiovascular drugs -- Diabetes drugs -- CNS drugs -- Cancer drugs -- Antiinflammatory and immunomodulatory drugs -- Anti-bacterial drugs -- Antiviral drug discovery. |
| Record Nr. | UNINA-9910822369803321 |
| Hoboken, N.J., : John Wiley & Sons, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Heterocyclic chemistry in drug discovery [[electronic resource] /] / edited by Jie Jack Li
| Heterocyclic chemistry in drug discovery [[electronic resource] /] / edited by Jie Jack Li |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (722 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico |
Heterocyclic compounds
Drug development |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-118-35444-3
1-118-50949-8 1-118-35443-5 1-118-35442-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 2. Pyrroles -- 3. Indoles -- 4. Furans, benzofurans, thiophenes, and benzothiophenes -- 5. Pyrazoles, pyrazolones, and indazoles -- 6. Oxazoles, isoxazoles, and oxazolidinones -- 7. Thiazoles and benzothiazoles -- 8. Imidazoles and benzimidazoles -- 9. Triazoles and tetrazoles -- 10. Pyridines -- 11. Quinolines and isoquinolines -- 12. Pyrazines and quinoxalines -- 13. Pyrimidines -- 14. Quinazolines and quinazolones. |
| Record Nr. | UNINA-9910463160003321 |
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Heterocyclic chemistry in drug discovery [[electronic resource] /] / edited by Jie Jack Li
| Heterocyclic chemistry in drug discovery [[electronic resource] /] / edited by Jie Jack Li |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (722 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) | LiJie Jack |
| Collana | New York Academy of Sciences |
| Soggetto topico |
Drug development
Heterocyclic compounds |
| ISBN |
1-118-35444-3
1-118-50949-8 1-118-35443-5 1-118-35442-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 2. Pyrroles -- 3. Indoles -- 4. Furans, benzofurans, thiophenes, and benzothiophenes -- 5. Pyrazoles, pyrazolones, and indazoles -- 6. Oxazoles, isoxazoles, and oxazolidinones -- 7. Thiazoles and benzothiazoles -- 8. Imidazoles and benzimidazoles -- 9. Triazoles and tetrazoles -- 10. Pyridines -- 11. Quinolines and isoquinolines -- 12. Pyrazines and quinoxalines -- 13. Pyrimidines -- 14. Quinazolines and quinazolones. |
| Record Nr. | UNINA-9910786720003321 |
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
